Popular Alternative :
Currently not enough data in this category. Generated by Gemini:- Genesis Therapeutics is a biotech startup that is using artificial intelligence (AI) to discover new drugs.
- The company was founded in 2019 by Evan Feinberg, a former researcher at Stanford University.
- Genesis Therapeutics has developed a proprietary AI platform called GEMS (Genesis Exploration of Molecular Space) that can be used to design and synthesize new drug candidates.
- The company has raised over $280 million in funding from investors such as Andreessen Horowitz, Rock Springs Capital, and T. Rowe Price.
- Genesis Therapeutics is currently focused on developing drugs for cancer and other diseases.
Here are some of the key features of Genesis Therapeutics' AI platform:
- Dynamic PotentialNet: This is a proprietary approach to predict potency, selectivity, and ADMET.
- Molecular generation engine: This allows Genesis scientists to search immense swaths of chemical space and offers significant advantages in addressing challenging and previously undruggable targets.
- Deep learning and molecular simulations: These are used to property prediction, and language models for molecular generation.
Genesis Therapeutics is a promising company that is using AI to revolutionize the drug discovery process. The company has a strong team of scientists and engineers, and its AI platform has the potential to discover new drugs that are more effective and less toxic than existing drugs.
The CEO of Genesis Therapeutics is Evan Feinberg. He is a former researcher at Stanford University, where he co-developed the PotentialNet algorithm for predicting the properties of molecules. He is also a co-author of the paper "A Generative and Predictive AI Platform for Small Molecule Drug Discovery".
I hope this helps! Let me know if you have any other questions.
End of Text